Research suggests compound administered during some bone marrow transplants elevates risks

Sep 21, 2010

Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute may spur debate about the risks associated with administering a specific compound in some forms of bone-marrow transplantation. The research is published in the current edition of Cell Host and Microbe.

The VGTI research team, led by institute director Jay Nelson, Ph.D., studies human cytomegalovirus, a virus that may infect up to 80 percent of the American population. The exact percentage of infected citizens is unknown due to the fact that the virus causes minor symptoms or no symptoms at all in most healthy people. However, the virus can pose a significant risk in people whose immune system has been compromised, such as those infected with HIV, or patients who have had their immune systems suppressed through chemotherapy or with anti-rejection medications during transplantation.

During this specific research project, Nelson, along with M. Shane Smith, Ph.D., a postdoctoral fellow in Nelson's lab and other colleagues focused on the impact of granulocyte-colony stimulating factor, or G-CSF, on the virus. G-CSF is a hormone frequently administered to transplant donors to stimulate stem cell growth and localization of blood prior to harvesting blood-borne stem cells.

While G-CSF-induced stem cell localization to the blood does provide a more comfortable means of stem cell donation compared to the previous method of harvesting cells directly from the bone marrow, previous studies have suggested that bone marrow transplantation performed with blood-borne stem cells places recipients at double the risk for HCMV and chronic graft-versus host disease.

The VGTI research team uncovered the mechanism behind this associated risk. Using a mouse model of the disease, the scientists determined that G-CSF causes HCMV, which is in a dormant or latent state in the bone marrow, to reactivate in , thereby placing stem cell recipients at elevated risk for HCMV transmission and disease.

"Because bone marrow recipients' immune systems are so significantly compromised, this risk is very significant," said Nelson. "We believe this research will generate discussion about the proper applications for G-CSF - which continues to provide benefits - but the risk associated must also be factored into patient care."

Explore further: Blood test predicts tissue injury in kidney transplant recipients

add to favorites email to friend print save as pdf

Related Stories

Molecule dictates how stem cells travel

Jan 14, 2006

U.S. researchers have defined a molecule that dictates how blood stem cells travel to the bone marrow and establish blood and immune cell production.

Recommended for you

Scientists aim to give botox a safer facelift

1 hour ago

New insights into botulinum neurotoxins and their interactions with cells are moving scientists ever closer to safer forms of Botox and a better understanding of the dangerous disease known as botulism. By comparing all known ...

Gut bacteria are protected by host during illness

2 hours ago

To protect their gut microbes during illness, sick mice produce specialized sugars in the gut that feed their microbiota and maintain a healthy microbial balance. This protective mechanism also appears to help resist or tolerate ...

User comments : 0